PDCD1 and Cirrhosis: There was no significant difference in baseline characteristics between MPR responder group and non-MPR responder group in terms of general status (age, gender, body mass index [BMI], alcohol abuse, history of liver diseases, and ECOG PS score), clinical data (Barcelona clinic liver cancer [BCLC] stage, Child-Pugh score, and baseline alpha fetoprotein [AFP] level), imaging findings (tumor diameter, cirrhosis, macroscopic portal vein invasion, extrahepatic metastases), surgical findings (strategy of hepatectomy and R0 resection) and the type of PD-1 inhibitors.